Radiomics: a Study of Outcome in Lung Cancer

Completed

Conditions studied: Lung Cancer

In brief

Aim of the study: The main aim is to collect data of patients with lung cancer, and to perform different analyses on this data. The data contains information on patient and tumor characteristics, imaging, and treatment characteristics. With this data it is possible to improve and validate the predictive model for survival and long term toxicity in lung cancer by multicentric prospective data collection. The long term aim, beyond this specific study, is to build a Decision Support System based on the predictive models validated in this study. Hypothesis: The general hypothesis is that we get a better prediction in terms of AUC (area under the curve) of survival and long term toxicity when we combine multifactorial variables. These variables consist of information from clinical data, imaging data, data related to treatment type and treatment quality.

Key facts

Study ID

NCT01302626

Run by

Maastricht Radiation Oncology

People needed

216

Starts

2010-03-01

Expected to finish

2014-03-01

Last updated by the study team

2017-03-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological or cytological proven lung cancer (small cell or non-small cell);
• 18 years or older;
• Informed consent according to national rules (US: written informed consent, NL: no objection rule)

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Gemelli Hospital Roma / Universita Cattolica del Sacre Cuore Rome — Rome, Italy
• Maastro clinic, University Hospital of Maastricht — Maastricht, Limburg, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.